Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
-
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and
-
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
-
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
-
GSK’s ZEJULA is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
ZEJULA (niraparib) has received conditional positive recommendations for reimbursement
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
-
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
-
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
-
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
-
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
-
ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer
ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer
-
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
-
GSK announces first participant vaccinated in Phase 3 Clinical Trials of its 5-in-1, Meningitis ABCWY vaccine candidate
GSK announces first participant vaccinated in Phase 3 Clinical Trials of its 5-in-1, Meningitis ABCWY vaccine candidate
-
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
-
Voluntary disclosure of payments to healthcare professionals in 2019
Voluntary disclosure of payments to healthcare professionals in 2019
-
GSK steps up for COVID-19
GSK has been closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus.
-
Save the Children Canada and GSK Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
Save the Children Canada and GSK Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
-
GSK Canada statement on supply
GSK Canada statement on supply
-
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
-
GSK Canada statement on COVID-19
GSK Canada statement on COVID-19
